Virtici

Executive Summary

Virtici LLC, a San Francisco-based life science company, is developing VTC-880, a first-in-class peptide for the prevention and treatment of periodontitis. The company was awarded a Phase 2 Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR/NIH), supporting the advancement of its lead candidate. Founded in 2019, Virtici operates at the intersection of digital health and AI/machine learning, though its core focus remains on peptide therapeutics for oral health. The Phase 2 SBIR grant provides non-dilutive funding to progress VTC-880 through preclinical and early clinical development, targeting a significant unmet need in periodontal disease. With no disclosed financials or valuation, Virtici is early-stage but validated by NIH support. The company's success hinges on successful Phase 2 data, potential partnerships, and regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2 clinical trial for VTC-88060% success
• 2027Partnership or licensing deal for VTC-88040% success
• Q3 2026Additional NIH grant or non-dilutive funding70% success